CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands		Common Stock	Additional Paid-in Capital	Notes Receivable From Stockholders	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total
Balance at beginning of period at Jun. 30, 2018		$ 28	$ 346,222	$ (85)	$ (1,618)	$ (353,260)	$ (8,713)
Balance at beginning of period (in shares) at Jun. 30, 2018		27,667
Interest on stockholder notes				(2)			(2)
Issuance of common stock upon exercise of stock options			975				975
Issuance of common stock upon exercise of stock options (in shares)		492
Issuance of common stock from public offering, net of issuance costs	[1]	$ 2	20,205				20,207
Issuance of common stock from public offering, net of issuance costs (in shares)	[1]	2,000
Stock-based compensation			1,197				1,197
Foreign currency translation adjustments					34		34
Net income						4,002	4,002
Balance at end of period at Mar. 31, 2019		$ 30	368,599	(87)	(1,584)	(345,442)	21,516
Balance at end of period (in shares) at Mar. 31, 2019		30,159
Balance at beginning of period at Dec. 31, 2018		$ 28	347,182	(87)	(1,620)	(346,840)	(1,337)
Balance at beginning of period (in shares) at Dec. 31, 2018		27,883
Issuance of common stock upon exercise of stock options			713				713
Issuance of common stock upon exercise of stock options (in shares)		276
Issuance of common stock from public offering, net of issuance costs	[1]	$ 2	20,205				20,207
Issuance of common stock from public offering, net of issuance costs (in shares)	[1]	2,000
Stock-based compensation			499				499
Foreign currency translation adjustments					36		36
Net income						1,398	1,398
Balance at end of period at Mar. 31, 2019		$ 30	368,599	(87)	(1,584)	(345,442)	21,516
Balance at end of period (in shares) at Mar. 31, 2019		30,159
Cumulative-effect adjustment upon the modified retrospective adoption of ASU No. 2016-16						3,816	3,816
Balance at beginning of period at Jun. 30, 2019		$ 31	371,099	(88)	(1,459)	(345,276)	24,307
Balance at beginning of period (in shares) at Jun. 30, 2019		30,478
Interest on stockholder notes				(1)			(1)
Issuance of common stock upon exercise of stock options			334				334
Issuance of common stock upon exercise of stock options (in shares)		142
Issuance of common stock in connection with employee stock purchase plan			448				448
Issuance of common stock in connection with employee stock purchase plan (in shares)		69
True up of issuance costs related to public offering			29				29
Stock-based compensation			1,393				1,393
Foreign currency translation adjustments					(99)		(99)
Net income						5,057	5,057
Balance at end of period at Mar. 31, 2020		$ 31	373,303	(89)	(1,558)	(340,219)	31,468
Balance at end of period (in shares) at Mar. 31, 2020		30,689
Balance at beginning of period at Dec. 31, 2019		$ 31	372,676	(89)	(1,650)	(342,086)	28,882
Balance at beginning of period (in shares) at Dec. 31, 2019		30,637
Issuance of common stock upon exercise of stock options			167				167
Issuance of common stock upon exercise of stock options (in shares)		52
Stock-based compensation			460				460
Foreign currency translation adjustments					92		92
Net income						1,867	1,867
Balance at end of period at Mar. 31, 2020		$ 31	$ 373,303	$ (89)	$ (1,558)	$ (340,219)	$ 31,468
Balance at end of period (in shares) at Mar. 31, 2020		30,689

[1] *Accrued liabilities of $185,000 included for stock issuance costs